Table 1.

Antifungals used.

		Fluconazole	Caspofungin	Anidulafungin	Micafungin	Ambisome	Voriconazole	Other
Episode∗ 1
	No. (%)	78 (64.5)	17 (14)	16 (13.2)	8 (6.6)	1 (0.8)	1 (0.8)	0 (0)
	Patient ages (mean)	60.3	67.6	61.3	72.9	0.01	40	0 (0)
	Route	PO/IV	IV	IV	IV	IV	IV
	No. days used (mean)	6.5	4.7	8.9	4.8	8	1	0(0)
	Outcome dead (no. (%))	20 (27.4)	7 (43.75)	8 (57.1)	2 (33.3)	1 (100)	0 (0)	0 (0)
Species specific [No. (%)]	Candida albicans	29 (59.2)	10 (20.4)	7 (14.3)	2 (4.1)	1 (2)	0 (0)	0 (0)
	C. glabrata	27 (69.2)	2 (5.1)	5 (12.8)	4 (10.3)	0 (0)	1 (2.6)	0 (0)
	C. parapsilosis	11 (55)	4 (20)	3 (15)	2 (10)	0 (0)	0 (0)	0 (0)
	C. tropicalis	5 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Others	6 (75)	1 (12.5)	1 (12.5)	0 (0)	0 (0)	0 (0)	0 (0)
Episode 2
	No. (%)	40 (57.1)	4 (5.7)	16 (22.9)	1 (1.4)	2 (2.9)	1 (1.4)	6 (8.6)
	No. days used (mean)	9.7	8.3	8.5	19	16	22	7.7
Episode 3
	No. (%)	13 (50)	1 (3.8)	1 (3.8)	1 (3.8)	2 (7.7)	7 (26.9)	1 (3.8)
	No. days used (mean)	7.8	19				10.83	2

^∗An episode is defined as a positive blood culture >21 days after the last positive culture or if a new Candida sp. isolated.